CAMBRIDGE, Mass., April 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results for its novel Smoothened antagonist, IPI-926, in a preclinical model of chondrosarcoma, a life-threatening cancer of the cartilage. The data demonstrated that IPI-926 inhibited tumor growth and led to tumor calcification in primary patient-derived chondrosarcoma tumor xenografts. These data, generated through a collaboration with Drs. Jay Wunder and Ben Alman at University of Toronto, were presented during a major symposium session at the American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 in Orlando, Florida.
